Neonatal atrial flutter: Three cases and review of the literature

Seda Yılmaz-Semerci¹, Helen Bornaun², Dilek Kurnaz¹, Burcu Cebeci¹, Aslan Babayigit¹, Gökhan Büyükkale¹, Merih Çetinkaya¹

Division of ¹Neonatology and ²Pediatric Cardiology, Department of Pediatrics, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey. E-mail: sedayilmazsemerci@gmail.com

Received: 27th April 2017, Revised: 2nd June 2017, Accepted: 4th June 2017


Atrial flutter (AFl) is known to be a seldom type of fetal and neonatal arrhythmia. Although it could end in severe morbidities such as hydrops fetalis or even death, with early prenatal diagnosis and prompt therapeutic approaches the majority of AFl cases show good prognosis. Neonatal AFl might be resistant to first step therapies. Therefore, secondary agents like flecainide, amiodarone, sotalol and cardioversion, if required, could be influential in perinatal tachyarrhythmia. In addition, close follow-up even after discharge is very important to keep all follow-up appointments. Herein, we present three cases of fetal/neonatal AFl in light of the literature and discuss the characteristics, diagnosis and treatment options.

Key words: atrial flutter, newborn, arrhythmia.

Tachycardia is defined as a persistent increase in heart rate above 180 beats/min and bradycardia is described a persistent heart rate less than 100 beats/min for neonates. Asymptomatic and temporary rhythm abnormalities occur constantly at the fetal and neonatal period but clinically significant arrhythmias are considerably rare. The incidence of arrhythmias for neonatal period is about 1% and 1–3% in late pregnancy.¹ The vast majority of supraventricular tachycardia (SVT) seen in neonatal age group without congenital cardiac anomalies are atrioventricular reentry tachycardia (AVRT) facilitated by an accessory pathway (AP) and atrial flutter (AFl) which is seldom encountered outside the neonatal period. The vast majority of these infants get free from symptomatic arrhythmia by the end of the first year of life, although recurrence in later childhood or adolescence is well recognized. Other less common mechanisms include abnormal automaticity, triggered activities are rare in early childhood, becoming more frequent with increasing age. Atrial flutter (AFl) is an uncommon type of fetal and neonatal arrhythmias based on the mechanism of reentry. It constitutes about 32% of all neonatal cardiac arrhythmias.² There are various etiologic factors for AFL. Although it may be asymptomatic, it may even result with severe heart failure requiring urgent therapy.¹ AFI cases are not accompanied by structural heart diseases generally. However, AFI cases that occur after first year of life are usually secondary to cardiac surgical procedures.³,⁴ AFI is usually diagnosed by electrocardiogram (ECG) with the presence of typical saw like waves of flutter. Atrial rates vary between 280-450 beats per minute (BPM).⁵,⁶ Majority of the cases are converted to sinusoidal rhythm easily by the usage of antiarrhythmic drugs or cardioversion.³,⁷ Although neonatal arrhythmias have relatively good prognosis, regular follow-up of the patients is crucial to prevent possible complications. Herein, we report three fetal/ neonatal cases managed successfully with antiarrhythmic medications and cardioversion. The aim of this study was to determine the possible risk factors, treatment options and prognosis for these cases. We also reviewed the literature about AFI in newborns.

An informed consent was received from the parents.

Case Reports

Case 1

A term male infant with a birth weight of 2,560 g was delivered by Cesarean section of
a 23-year-old primiparous mother. The APGAR scores were 9 and 10 at 1st and 5th minutes, respectively. In prenatal history, fetal arrhythmia was detected (Fig. 1). His heart rate was detected as 225 beats per minute (bpm) at the first physical examination. ECG demonstrated 2:3:1 atrioventricular conduction AFl (atrial rate 485/bpm, ventricular rate 225/bpm) (Fig. 2). Therefore, oral propranolol therapy with a dosage of 2 mg/kg/day was started. Ejection fraction (EF) was 60%. Due to the recurrence of AFI, cardioversion was performed with 1 joule/kg and the rhythm converted to normal. At the follow up, propranolol was stopped due to the frequent recurrent AFI's and sotalol therapy was started. In the 36-48 hours of sotalol therapy, cardioversion was performed again with 2 joule/kg for the second time as AFI continued. After that, normal sinus rhythm was detected on ECG. At postnatal day 10, the patient was discharged with sotalol therapy. No AFI was detected in the 1-year follow up and corrected QT (QTc), Holter ECG and echocardiography (ECHO) were all found to be normal. Therefore, sotalol therapy was stopped.

**Case 2**

A term, male infant was born by C-section because of fetal distress from the first pregnancy of 27-year-old mother. At the physical examination, both tachypnea (60/min) and tachycardia (250/bpm) were determined. Nasal continuous positive airway pressure (NCPAP) was performed. As ECG showed supraventricular tachycardia (SVT), intravenous adenosine with a dosage of 0.1mg/kg was administered. Because of persistence of SVT, cardioversion was performed for once. After conversion to normal sinus rhythm, propranolol therapy was started. At the third hour of propranolol therapy, SVT recurred; so second cardioversion was performed successfully with the establishment of sinus rhythm. At postnatal day 2, weaning from NCPAP to room air was performed. SVT did not occur and the infant was discharged at the 7th day of life with propranolol therapy. AFI did not repeat in the 1-year follow up and corrected QT (QTc), Holter ECG and echocardiography (ECHO) were all found to be normal. Therefore, therapy was ceased.

**Case 3**

A female neonate was born at 34 weeks of gestational age by C-section because of hydrops fetalis from the first pregnancy of 22-year-old mother. Her birth weight was 2,620 g. She was intubated in delivery room due to respiratory distress. At her first physical exam, in addition to tachypnea, her heart rate was found as 254/bpm. As ECG detected AFI, adenosine was administered for twice. After initiation of propranolol therapy, cardioversion was also performed due to the recurrent AFI’s. As AFI remained resistant to these therapies, amiodarone therapy was started. Normal sinus rhythm was detected after 1 hour of amiodarone administration. After 24 hours without AFI attack, intravenous amiodarone therapy was replaced with oral treatment. At the 14th day of follow up, only two short SVT attacks were detected on ECG monitor which lasted for 2 or 5 minutes and resolved spontaneously. The patient was discharged at 18th day of life and in good general state with propranolol and amiodarone therapy. AFI did not repeat during the first year of follow up. Corrected
Atrial flutter in newborn generally occurs in the first 7 days of life. Sex distribution is known to be equal. Atrioventricular re-entry is the most common mechanism determined for supraventricular tachycardia in both the fetus and newborn. Fetuses and neonates with atrial flutter or ectopic atrial tachycardia are more likely to be macrosomic or be born to diabetic mothers than the general population. But neither macrosomia nor gestational diabetes was present in our cases. Important factors for clinical course are beginning of the signs, duration of AFl, and degree of ventricle response to AFl. While the patient is not stable hemodinamically, cardioversion is the treatment of choice, but if the clinical state is stable, antiarrhythmic drugs are suggested.

Our first case had no cardiac abnormality or clinical symptom of heart failure. Majority of fetal tachycardia detected before 36 weeks of gestation can be treated by maternal administration of antiarrhythmic drugs such as digoxin and dexamethasone. Dexamethasone is recommended in case of severe hydrops fetalis but its neurologic side effects should be taken into consideration. Our cases were detected after 36th gestational week so maternal therapy did not start. After 36th gestational week postnatal medications, transesophageal overdrive pacing, or synchronized direct current cardioversion (DCC) might be the choices of treatment. Cardioversion for neonatal AFl is often successful with as little as 0.25-0.5 J/kg with the current biphasic devices. However it is use in neonates has not been approved yet, ibutilide is reported to be effective in some cases of AFl. It is also reported that propafenone therapy and multiple external electrical cardioversion could be successful for refractory neonatal atrial flutter. Digoxin has been recommended in the treatment of neonatal AFl. But because of the raised risk of ventricular tachycardia accompanying to cardioversion after digitalization we did not use digoxin in our case 1 for the first choice. Though patients were stabile hemodinamically and AFl did not last for a long-time, anticoagulant therapy were not required. We used propranolol, cardioversion, sotalol and then cardioversion again. Direct current cardioversion appears to be most effective at establishing sinus rhythm. After these therapies sinusoidal rhythm detected on patient’s ECG and his general status went on normal. Different studies reported the success ratio of cardioversion at returning AFl into normal sinusoidal rhythm is to be approximately 90%. In patient 1, because of recurrent AFl episodes after the combination therapy of propranolol and cardioversion, a combination therapy of sotalol and cardioversion were performed then AFl episodes disappeared. Similar to our results, plenty of studies have shown that sotalol is the most effective drug in AFl treatment. Dikensoy et al. reported a fetal AFl case healed by the use of sotalol confidently after failing with digoxin. It is pointed out that sotalol is a good second choice of antiarrhythmic agent to use safely at perinatal term because it has no inotropic effect. In accordance with the recent literature, successful results of our cases might be supportive for the combination therapy of propranolol, amiodarone, flecainide and cardioversion in refractory AFl. Therefore, it is being an efficient option of treatment. Amiodarone is associated with electromechanical dissociation, amiodarone-induced pulmonary toxicity and transient hypothyroidism. Maternal drug use of cocaine and/or opiate is found to be associated with isolated atrial flutter. In the second case of ours, maternal drug addiction is thought to be the reason of AFl of the baby. Maternal lithium ingestion is thought to be related with fetal AFl so assessment of all infants born to mothers on lithium treatment during pregnancy should include an electrocardiogram. Hypophosphatemic familial rickets (vitamin D-resistant rickets) of a female fetus, associated with atrial flutter and congestive heart failure is also reported.

AFl in neonate might be resistant to first step therapies such as beta-blockers (esmolol, propranolol) or digoxin. Therefore secondary agents like flecainide, amiodarone, sotalol and cardioversion, if required, could be influent in perinatal tachyarrhythmia. In addition, close follow-up even after discharge is very important and one should try to keep all follow up appointments. Follow-up is needed to check
for signs of the arrhythmia recurrence, as well as possible side effects of certain treatments. Infants with AFl generally have an excellent prognosis once in sinus rhythm with a low risk of recurrence, and long-term antiarrhythmic therapy is unlikely to be necessary.

REFERENCES